The Dogo Argentino (DA) is the first and only breed from Argentina recognized worldwide. Although its morphologic features have been well established, its normal reproductive parameters are not clearly known. The aim of this study was to determine the main DA bitch reproductive parameters. One hundred and forty-nine surveys were obtained from breeders from Córdoba province, Argentina: one for each intact DA bitch from 1 to 14 years old. The DA bitch reached puberty at an average of 8.93 months. The mean duration of vulval bleeding found in this study was 11.11 days. The clinical signs characteristic for proestrous-estrous were vulval edema (89.93%), bleeding during the time of mating (32.21%), holding the tail to the side (95.30%), and docility during mating (85.91%). DA bitches had a whelping rate of 84%. Out of 299 pregnancies, 89.30% exhibited a normal parturition, 6.69% presented dystocia, 2.68% needed Cesarean section, and 1.34% aborted. In conclusion, the reproductive parameters of the DA bitch are similar to those identified for other large breeds. DA often showed a prolonged vulval bleeding longer than proestrus. Its high whelping rate, its low incidence of dystocia, and its good maternal ability define the DA as a good reproductive breed with normal reproductive functions.
This study compared the efficiency of the aromatase inhibitor, anastrazole, with the antioestrogenic receptor blocker, tamoxifen, on normal (NRL) and hyperplastic prostate glands. Forty healthy dogs were classified as NRL (n = 18) or abnormal (ABN) with benign prostate hyperplasia (n = 22). The dogs were randomly assigned to one of the following six groups, treated for 60 days; oral placebo for normal (NRL-PLC; n = 6) and abnormal (ABN-PLC; n = 6), oral anastrazole 0.25-1 mg/day, for normal (NRL-ANZ, n = 6) and abnormal (ABN-ANZ, n = 8) and oral tamoxifen citrate 2.5-10 mg/day for normal (NRL-TMX; n = 6) and abnormal (ABN-TMX; n = 8) dogs. The dogs were evaluated before treatment and then monthly for 4 months. At the end of the treatment, the prostatic volume decreased by 28.5 +/- 4.3%, 21.6 +/- 6.3% and 0.7 +/- 1.0% in the ABN-TMX, ABN-ANZ and ABN-PLC (p < 0.01), respectively. From then on, prostatic volume began to increase without reaching pre-treatment values at the end of the study. In the ABN animals, there were no differences for this parameter between ANZ and TMX treatment (p > 0.1), whereas in the NRL animals ANZ produced a less pronounced decrease (p < 0.05), libido, testicular consistency and scrotal diameter decreased during treatment in the TMX group (p > 0.05). These parameters and sperm volume, count, motility and morphological abnormalities remained unaltered throughout the study in the ANZ and PLC groups (p > 0.05). There were no haematological nor biochemical side effects. Anastrazole might offer a safe and effective alternative for the medical management of dogs with benign prostatic hyperplasia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.